000 04325nam a22004455i 4500
001 978-1-59259-915-8
003 DE-He213
005 20161121230702.0
007 cr nn 008mamaa
008 100301s2006 xxu| s |||| 0|eng d
020 _a9781592599158
_9978-1-59259-915-8
024 7 _a10.1385/159259915X
_2doi
050 4 _aRC261-271
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a614.5999
_223
245 1 0 _aBiomarkers in Breast Cancer
_h[electronic resource] :
_bMolecular Diagnostics for Predicting and Monitoring Therapeutic Effect /
_cedited by Giampietro Gasparini, Daniel F. Hayes.
264 1 _aTotowa, NJ :
_bHumana Press,
_c2006.
300 _aXII, 342 p. 22 illus.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCancer Drug Discovery and Development
505 0 _aGeneral Topics -- Guidelines for the Design of Clinical Studies for the Development and Validation of Therapeutically Relevant Biomarkers and Biomarker-Based Classification Systems -- Analytical Aspects of Biomarker Immunoassays in Cancer Research -- Tissue Microarrays -- Assays for Gene Expression and Post-Translational Protein Abnormalities -- Gene Expression Profiling with DNA Microarrays -- Assays for DNA Abnormalities -- Assays for Gene Amplification -- Tissue Predictive Biomakers -- Cell Kinetics -- Urokinase-Type Plasminogen Activator and PAI-1 -- Predictive Value of c--erb-B2 for Endocrine Therapy and Chemotherapy in Breast Cancer -- erb-B2 as a Therapeutic Target -- The Epidermal Growth Factor Receptor Pathway as a Selective Molecular-Targeted Treatment in Human Breast Cancer -- p53 as a Prognostic and Predictive Indicator -- Predictive Biomarkers in Body Fluids -- Occult Metastatic Cells in Breast Cancer Patients -- Circulating HER2/neu -- Circulating Vascular Endothelial Growth Factor -- Detection of Early Tumor Dissemination in Patients With Breast Cancer -- Future Directions -- New Technologies/New Markers/New Challenges.
520 _aIt is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy.
650 0 _aMedicine.
650 0 _aCancer research.
650 1 4 _aBiomedicine.
650 2 4 _aCancer Research.
700 1 _aGasparini, Giampietro.
_eeditor.
700 1 _aHayes, Daniel F.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781588292278
830 0 _aCancer Drug Discovery and Development
856 4 0 _uhttp://dx.doi.org/10.1385/159259915X
912 _aZDB-2-SBL
950 _aBiomedical and Life Sciences (Springer-11642)
999 _c502434
_d502434